Green AI Cloud and Cerebras Systems Bring Industry-Leading AI Performance and Sustainability to Europe
14.12.2022 15:00:00 CET | Business Wire | Press Release
Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Green AI Cloud, the most sustainable super compute platform in Europe, today announced the availability of Cerebras Cloud at Green AI. As the first cloud computing provider in Europe to offer the industry-leading CS-2 system, Green AI customers now can easily train GPT-class models much faster than traditional cloud service providers and with significantly less environmental impact.
The Green AI Cloud is a pioneer in clean energy compute. The Green AI Cloud uses only renewable energy (Hydro and Wind Power) in its datacenter placed in the north of Sweden and converts the excess heat from operations into a heated liquid for industrial product manufacturing– resulting in a negative CO2 footprint. With its new Cerebras Cloud offering, customers can now train leading generative Transformer (GPT)-class models, including GPT-J, GPT-3 and GPT-NeoX, with the promise of equivalent carbon offsets through Green AI’s uniquely sustainable and “carbon-intelligent” cloud.
“We are thrilled to offer our customers access to the industry-leading CS-2 system, powered by the 850,000 AI core WSE processor, which will greatly reduce their initial programming work and enable easy integration with existing workflows,” said Jacob Bostrom, Founder and CEO of Green AI Cloud. “By providing the latest and fastest AI technology through our partnership with Cerebras, we continue to not only drive the future of AI innovation, but also the next era of sustainability and environmental responsibility.”
Energy Efficiency and CO2 Reduction – Examples
- Cerebras CS-2 is 3,5 times more energy efficient than NVIDIA® A100 for multi-billion parameter NLP models, including GPT-J, GPT-3 and GPT-3XL.
- Cerebras CS-2 is 6 times more energy efficient than NVIDIA V100 for AI model 'BERT Base' (according to University of Massachusetts Amherst and MIT Technology Review).
- Using Green AI Cloud compared to other European Cloud providers when training a single deep learning AI transformer model, the resulting carbon offset is equivalent to the annual CO2 absorption from 11 000 trees!
Safeguarding Data Security and Privacy Regulations
The EU has some of the strictest data privacy and security rules in the world. A cloud provider based in the EU, such as Green AI Cloud, enables customers across the EU to benefit from Cerebras’ industry-leading AI compute and stay within the data privacy structures. Customers across segments, from pharmaceutical to finance services, and energy to heavy manufacturing, now have push-button access to the Cerebras CS-2 system and can use it by the day, week, or month.
“Cerebras is committed to delivering AI compute – via cloud, on premise or hybrid – to our customers around the world in the most environmentally efficient way possible,” said Andrew Feldman, co-founder and CEO, Cerebras Systems. “As the leader in energy efficient AI compute, it was an obvious choice to partner with and deliver AI compute to the Green AI Cloud.”
Cerebras recently announced its AI Model Studio, as well as partnerships and wins with Sandia National Laboratory and generative AI pioneer Jasper. At the NeurIPS Conference earlier this month, Cerebras broke new ground demonstrating high sparsity training on GPT class models, showing that GPT models can be trained at 90% sparse, using a fraction of the FLOPs and time, and still achieve the same accuracy.
With customers in North America, Asia, Europe and the Middle East, Cerebras is delivering industry leading AI solutions to a growing roster of customers in the enterprise, government, and high-performance computing (HPC) segments, including Jasper, GSK, AstraZeneca, TotalEnergies, nference, Argonne National Laboratory, Lawrence Livermore National Laboratory, Pittsburgh Supercomputing Center, Leibniz Supercomputing Centre, National Center for Supercomputing Applications, Edinburgh Parallel Computing Centre (EPCC), National Energy Technology Laboratory, Sandia National Laboratory, and Tokyo Electron Devices.
For more information, please visit https://greenai.cloud/.
About Green AI Cloud
Green AI Cloud - a European Cloud Service Provider offering AI Super Compute for the largest AI models available. Green AI Cloud delivers superior cost efficiency while being the greenest CSP in Europe – fully capitalizing on its location in the northern part of Sweden that gives access to green energy, carbon offset facilities and world leading datacenter infrastructure.
About Cerebras Systems
Cerebras Systems is a team of pioneering computer architects, computer scientists, deep learning researchers, and engineers of all types who have come together to build a new class of computer system. That system is designed for the singular purpose of accelerating AI and changing the future of AI work forever, enabling customers to accelerate their deep learning work by orders of magnitude.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005263/en/
Contact information
Kim Ziesemer
Email: pr@zmcommunications.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
